Corteva has exclusive development and commercialization rights to Lavie Bio’s biofugnicide lineup.
Lavie Bio is based in Israel and is the a subsidiary of Evogene Ltd. Its biofungicide candidates target fruit rots and powdery mildew.
The licensing agreement comes after two years of the companies conducting independent field trials.
“When you have a world-class R&D program, like we do at Corteva Agriscience, it allows you to move fast and bring on new opportunities that will help farmers meet the demands of an ever-changing food system,” said Sam Eathington, Executive Vice President, Chief Technology and Digital Officer, Corteva Agriscience. “This agreement gives us yet another avenue to provide better solutions to farmers now, and in the future.”
Lavie Bio uses a propertairy platformed powered by Evogene’s artificial intelligence system.
“Our licensing agreement solidifies the collaboration between both companies, leveraging Corteva’s impressive scale-up capabilities and market leadership, in conjunction with Lavie Bio’s distinctive discovery expertise powered by Evogene’s MicroBoost AI tech-engine and comprehensive product development capabilities” said Amit Noam, CEO of Lavie Bio. “This agreement not only highlights Lavie Bio’s technological capabilities but also enables us to swiftly introduce groundbreaking ag-biological solutions that benefit farmers, consumers, and the environment. “
